Abstract: Methods are presented for selecting a subject for treatment with a 2-arylbenzimidazole compound of Formula I, or salt, hydrate, deuterated analog, or fluorinated analog thereof, based on the inflammatory phenotype of circulating myeloid cells. Methods are also provided for treating, slowing the progression of, and delaying the onset of neurodegenerative disease in a subject who has not been diagnosed with a neurodegenerative disease but is at risk of developing a neurodegenerative disease or cognitive impairment, comprising selecting the subject for treatment based on the inflammatory phenotype of circulating myeloid cells and administering a therapeutically effective amount of compound of Formula I or salt, hydrate, deuterated analog, or fluorinated analog thereof.

Abstract: The disclosure provides methods of treating a patient who has, or who is at risk for developing, systemic immune activation, including cytokine release syndrome (CRS) and sepsis. The method comprises administering a therapeutically effective amount of a compound of Formula I the patient.

Abstract: Methods are provided for reducing neuroinflammation and/or treating a neurodegenerative disease in a subject. The methods comprise orally administering to a subject with neuroinflammation and/or a neurogenerative disease a pharmaceutical composition comprising the compound of formula (I) (TQS-168), or a pharmaceutically acceptable salt thereof, in amount that provides defined plasma and brain exposures of TQS-168 and/or an active metabolite following administration.

Abstract: The use for the manufacture of a medicament for preventing unwanted coagulation during surgery, and particularly a Coronary Artery By pass Graft (CABG) procedure, of boronic acids of formula (I), and salts, prodrugs and prodrug salts thereof; wherein Y comprises a moiety which, together with the fragment —CH(R9)—B(OH)2, has affinity for the substrate binding site of thrombin; and R9 is a straight chain alkyl group interrupted by one or more ether linkages and in which the total number of oxygen and carbon atoms is (3, 4, 5) or (6) or R9 is —(CH2)m—W where m is (2, 3, 4) or (5) and W is —OH or halogen (F, CI, Br or I).

Abstract: Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.

Abstract: Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.

Abstract: Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)—Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.

Abstract: Salts of a peptide boronic add drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.

Abstract: Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.

Abstract: Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.

Abstract: Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.

Abstract: Salts of a peptide boronic acid drug, for example of Cbz—(R)—Phe—(S)—Pro—(R)—Mpg—B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.